Title:

Sanofi COVID-19 Vaccine (VidPrevtyn® Beta)

Description:

VidPrevtyn Beta is not currently being routinely supplied but may be offered as an alternative when an mRNA vaccine is not considered clinically suitable. For this indication it is now recommended for those aged 18 years and above (VidPrevtyn Beta is licensed for individuals 18 years of age and older but its use as an alternative vaccine was previously restricted to those aged 65 years and above).

There have been no changes to the Summary of Product Characteristics (SPC) for this vaccine since it was first licensed.

This course provides specific information about VidPrevtyn® Beta (recombinant, adjuvanted) COVID-19 vaccine, common abbreviated name VidPrevtyn® Beta, manufactured by Sanofi Pasteur. It is designed to provide healthcare workers with the knowledge they need to administer this vaccine safely and effectively to eligible adults.

This course covers key information including how the vaccine works, how it should be stored, prepared and administered and any contraindications, precautions and potential vaccine reactions.

The Core Knowledge session covers key areas including legal aspects of vaccination. The Core Knowledge session therefore must be completed in addition to this vaccine-specific session.
After completing this COVID-19 vaccine Sanofi VidPrevtyn® Beta specific session, you should complete the accompanying knowledge assessment.

It is important to note that the different COVID-19 vaccines available have different storage, preparation and administration requirements. You must be familiar with the specific recommendations for the COVID-19 vaccine you are delivering.

Hierarchy:

Coronavirus (COVID-19) > COVID-19 Vaccination > Sanofi COVID-19 Vaccine (VidPrevtyn® Beta)

Keywords:

COVID, 19, coronavirus, vaccine, vaccination, immuniser, immunisation, Sanofi Pasteur, VidPrevtyn, beta, recombinant, adjuvanted

Created:

27 Mar 2023

Updated:

27 Mar 2023